

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: mmora@miscorp.com.au
Website: www.biotron.com.au

19 October 2026

The Manager Companies
ASX Limited
20 Bridge Street
SYDNEY NSW 2000

(3 pages by email)

Dear Sir / Madam

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board of Biotron Limited ('Biotron' or the 'Company') is pleased to announce the appointment of Dr Michael J. Thurn as Non-Executive Director, effective today.

Dr Michael Thurn is a biotechnology executive and non-executive director with more than 25 years' experience spanning drug discovery, preclinical and clinical development, regulatory strategy, capital raising, licensing and company building. He is a former Senior Toxicologist with the Therapeutic Goods Administration and has extensive experience advancing novel therapeutics through development and regulatory pathways.

Dr Thurn is currently a Non-Executive Director of Arovella Therapeutics Limited and Erasca Australia Pty Ltd, and a Primary Reviewer with Bellberry Limited's Human Research Ethics Committee. He was Managing Director and Chief Executive Officer of Neurizon Therapeutics Limited from 2024 to 2026 and has previously held senior executive roles at Botanix Pharmaceuticals, Mimetica, Spinifex Pharmaceuticals, Cytopia Research and Xenome.

His career includes leading and supporting multiple US FDA IND programs, substantial capital raisings and strategic transactions, including founding Spinifex Pharmaceuticals and contributing to the Novartis transaction that ultimately valued the company at US\$700 million, as well as playing a role in Cytopia's A\$274 million JAK3 licensing agreement with Novartis.

Dr Thurn holds a PhD, a Bachelor of Applied Science (Honours Class I) and a Bachelor of Applied Science (Biomedical Science), all from the University of Technology Sydney.

Biotron's Chairman, Paul Kasian, said, "Michael Thurn is a welcome addition to the Biotron Board. He adds substantial expertise and experience at an important stage of the Company's new developments."

In accordance with Listing Rule 3.19A, I attach an Appendix 3X, Initial Director's Interest Notice, for Dr Michael J. Thurn.

This announcement has been approved by the Board of Biotron.

Yours faithfully,



Marcelo Mora
Company Secretary.

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	BIOTRON LIMITED
ABN	60 086 399 144

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael J. Thurn
Date of appointment	19 October 2026

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil

+ See chapter 19 for defined terms.

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.	Number & class of Securities
Nil	

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

+ See chapter 19 for defined terms.